web analytics

Bulls Take Charge of Creative Medical Technology Holdings Inc (OTCMKTS: CELZ)

0

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is heating up and moving northbound after the Company reported new data demonstrating effective suppression of stroke associated pathological molecules by AmnioStem® universal donor stem cells.  Experiments have shown that AmnioStem® potently blocks production of cytokines which are associated with brain damage after stroke. The current studies show that AmnioStem® elicits these cytokine changes based on its activities on macrophages. CELZ CEO Timothy Warbington stated the Company plans to submit this data for publication and include it in its upcoming FDA IND submission.”

CELS is an exciting Company who’s flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. CELZ has runner in its blood and a long history of huge moves and is a volume leader regularly among the top most traded on the OTCBB.

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is a commercial stage biotechnology company focused on urology, orthopedics and neurology using adult stem cell treatments.  CMT was originally created as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction which it acquired from CMH in February 2016. Subsequently the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing amniotic stem cells, and the treatment of neurologic disorders and lower back pain using various types of stem cells through its  AmnioStem LLC and StemSpine, LLC subsidiaries.

CELZ markets and sells its CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Its CaverStem® and FemCelz® kits are currently available through physicians at 12 locations in the United States and Europe. The Company is focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the Unites States, Europe and South America, and commercializing its StemSpine® treatment for lower back pain.

To Find out the inside Scoop on CELZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CELZ

CELZ has been busy; in July they completed the preclinical studies assessing the anti-inflammatory and neuroregenerative activities of AmnioStem™. These studies complete what the Company believes is necessary for filing an Investigational New Drug (IND) application with the FDA to initiate clinical trials in patients with stroke. The studies, which were conducted by Company scientists and collaborators demonstrated that AmnioStem™ amniotic fluid stem cells are potent suppressors of brain inflammation from cells called microglial cells. It is believed that microglial cells contribute to the death of brain tissue subsequent to stroke. The data provides a mechanistic explanation for the ability of AmnioStem™ cells to suppress stroke associated pathology in animal models.

On August 20 CELZ reported new data demonstrating effective suppression of stroke associated pathological molecules by AmnioStem® universal donor stem cells.  Experiments have shown that AmnioStem® potently blockes production of cytokines which are associated with brain damage after stroke. In contrast to previously attempted approaches, the data disclosed today demonstrate that AmnioStem® effectively reprograms the macrophages from a pathological to a reparative role. Previous studies performed by the Company at its BioLabs research facility in San Diego, showed that AmnioStem® cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12 as compared to other stem cells1.  The current studies show that AmnioStem® elicits these cytokine changes based on its activities on macrophages.

CELZ CEO Timothy Warbington stated:  “Knowing the specific mechanisms by which our cells work in stroke positions us ahead at several levels: Firstly, it allows us a more straightforward pathway to FDA clearance; Secondly, it allows for development of rationalized medical therapeutics and identification of potentially synergistically acting medications; and Thirdly, it allows for enhanced intellectual property protection. We plan to submit this data for publication and include it in our upcoming FDA IND submission.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently moving up the charts CELZ is an exciting story developing in small caps; CELZ flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. The erectile dysfunction market is booming! According to a recent report from ResearchAndMarkets.com, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023. CELZ currently has products under development that address billion dollar markets and its pipeline includes CaverStem, FemCelz, AmnioStem and StemSpine. CELZ CEO Timothy Warbington put it best; “Knowing the specific mechanisms by which our cells work in stroke positions us ahead at several levels: Firstly, it allows us a more straightforward pathway to FDA clearance; Secondly, it allows for development of rationalized medical therapeutics and identification of potentially synergistically acting medications; and Thirdly, it allows for enhanced intellectual property protection. We plan to submit this data for publication and include it in our upcoming FDA IND submission.” We will be updating on CELZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CELZ.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CELZ either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.